Story
Stripe and Advent's $53B Bid for PayPal Seen as 'Too Low' by Wall Street

Summary
A joint $53 billion takeover offer for PayPal from Stripe and Advent International is being viewed as an opening bid, with PayPal's stock trading at a significant discount to the $60.50 per share offer price.
A consortium including payments giant Stripe and private equity firm Advent International has tabled a $53 billion takeover offer for PayPal (PYPL), but the market is signaling that the initial price is not enough. The joint bid, priced at $60.50 per share, has sent PayPal's stock surging, yet it continues to trade at a notable discount, reflecting investor skepticism that the deal will close at its current terms.
The Proposed Transaction
The offer represents a roughly 28% premium to PayPal's closing price before the news broke. According to the proposal, Stripe and Advent would take a 50/50 stake in the payments company, with no plans to break up its assets. The bid is supported by approximately $50 billion in committed bank financing.
CNBC also reported that Block could potentially join the consortium as an equity contributor. Following the announcement on July 15, PayPal shares jumped over 20%. However, the stock's current price of $56.77 remains well below the offer, indicating that the market is pricing in significant risk that the deal either fails or will require a higher bid to succeed.
Analyst Consensus: An Opening Move
The prevailing view among Wall Street analysts is that the $60.50 offer is a starting point for negotiations rather than a final price. The sentiment is that PayPal's board is unlikely to accept the initial terms.
Ad- Cantor Fitzgerald suggested a sum-of-the-parts valuation implies a fair price is closer to $70 per share.
- William Blair analysts stated they do not expect PayPal's CEO to accept the current bid, viewing a potential $70 price as possible but having a low probability.
- Investor Michael Burry called the bid "simply too low," placing his intrinsic value for PayPal between $75–$80 in a conservative scenario and arguing a final bid would need to be near $100 to include a standard control premium.
Strategic Logic and Next Steps
For Stripe, the acquisition offers a path to immense scale, immediately adding PayPal's 439 million active accounts and Braintree's approximately $700 billion in payment volume. However, analysts at William Blair noted that absorbing PayPal could dilute Stripe's own 34% volume growth seen in 2025 and potentially compress its margins.
The focus now shifts to PayPal's upcoming board meeting on July 20. Analysts at Clear Street noted that the news leak ahead of the meeting could pressure the board to formally engage with the bidders. The spread between PayPal's market price and the offer price serves as a live indicator of the market's confidence, currently pricing in a roughly 60-65% chance of the deal's completion at the proposed price.
Read next
More on Stocks
Apple's Tim Cook Views Australia's Social Media Curbs as 'World-Leading,' PM Albanese Says
Apple Executive Chair Tim Cook praised Australia's pioneering online safety measures as "world-leading," according to Prime Minister Anthony Albanese following a meeting at the tech giant's California headquarters.

Venezuela's Interim Government Signs Energy MOU with TotalEnergies
Venezuela's interim government signed a memorandum of understanding with French energy major TotalEnergies, the latest in a series of deals aimed at attracting foreign investment back into the nation's vast oil sector.

Huawei Unveils Advanced Power and Cooling Solutions for AI Data Centers
Huawei has launched a new suite of energy infrastructure and thermal management products for AI data centers, signaling a strategic shift towards integrated power storage and intelligent liquid cooling systems to meet the demands of high-density computing.

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO
Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.